Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

(2013) S. Calanna et al.   DIABETOLOGIA

Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects

(2012) Katrine B. Hansen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

(2011) J. J. Holst et al.   DIABETES CARE

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Incretin Hormone and Insulin Responses to OralVersusIntravenous Lipid Administration in Humans

(2011) Ola Lindgren et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes

(2010) Z. Schroner et al.   DIABETES OBESITY & METABOLISM

New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

(2010) Y. M. Cho et al.   DIABETOLOGIA

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes

(2010) Soushou LEE et al.   ENDOCRINE JOURNAL

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

(2010)   LANCET

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications

(2009) N. Irwin et al.   DIABETOLOGIA

Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men

(2009) Charlotte Brøns et al.   JOURNAL OF PHYSIOLOGY-LONDON

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION

Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort

(2008) Josina M. Rijkelijkhuizen et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

Dorothy Hodgkin Lecture 2008 Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesitydiabetes?

(2008) P. R. Flatt   DIABETIC MEDICINE

Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action

(2008) K. Færch et al.   DIABETOLOGIA